TORONTO, ONTARIO--(Marketwired - June 17, 2014) - Medifocus Inc. ( Medifocus or the Company ) (TSX VENTURE:MFS)(OTCQX:MDFZF) is pleased to announce that it has applied to the TSX Venture Exchange (the Exchange ) to extend the expiry date of 13,056,997 outstanding common share purchase warrants issued pursuant to the private placement announced November 30, 2012 and to extend the expiry date of 22,196,795 outstanding common share purchase warrants issued pursuant to the private placement announced July 6, 2012 by one year. Both sets of warrants entitle the holder thereof to acquire one common share of Medifocus at a price of $0.20.
If the Exchange approves the extensions, the Company will be permitted to extend the term of the warrants from January 14, 2015 to January 14, 2016, in the first instance and from September 21, 2014 to September 21, 2015, in the second instance. All other terms and conditions of the Warrants will remain unchanged and in full force and effect.
On June 6, 2014, the Company received approval to extend the expiry date of 40,567,253 outstanding common share purchase warrants to June 15, 2015, as previously announced. These are comprised of 18,367,253 outstanding common share purchase warrants issued pursuant to the private placement announced June 8, 2012 and 22,200,000 outstanding common share purchase warrants issued pursuant to the private placement announced Jun 21, 2012. Both sets of warrants entitle the holder thereof to acquire one common share of Medifocus at a price of $0.20.
About Medifocus, Inc.
Medifocus owns two fully developed technology platforms with comprehensive United States and international patent protection: (i) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The United States Food and Drug Administration (FDA) approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. Medifocus' APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, has received approval from the FDA and Health Canada to conduct the pivotal Phase III clinical trials. Medifocus believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers. Please visit www.medifocusinc.com , www.prolieve.com and http://www.facebook.com/pages/Medifocus-Inc-C...5028715627 for more details.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
